Health Canada has authorized an adapted vaccine from Novavax for people age 12 and older to target a variant of COVID-19.
Vaccine targets XBB.1.5 variant circulating globally earlier this year
Health Canada has authorized an adapted vaccine from Novavax to prevent COVID-19 in people age 12 and older.
The vaccine uses a traditional approach to defend the body against COVID.
It contains a version of the viral spike protein and is also authorized as a booster for those 18 and older, according to Health Canada’s webpage.
Novavax’s first vaccine to protect against COVID-19, known as Nuvaxovid, was authorized for use in Canadians 18 and over by Health Canada in February 2022.
Pfizer-BioNTech and Moderna’s vaccines have also been updated to target XBB.1.5 and are approved for use in Canada.